Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166643 | 0.84 | RXFP1 (0.72) | RXFP1MAPTSMN1; SMN2LMNATP53 | |
| SCHEMBL18166677 | 0.83 | RXFP1 (0.70) | RXFP1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL18166592 | 0.79 | MAPT (0.74) | RXFP1MAPTSMN1; SMN2LMNATP53 | |
| SCHEMBL18166652 | 0.79 | RXFP1 (0.65) | RXFP1MAPTTP53TSHRKDM4E | |
| SCHEMBL10114670 | 0.78 | MAPT (0.82) | RXFP1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL27793543 | 0.78 | MAPT (0.79) | RXFP1MAPTSMN1; SMN2LMNATSHR | |
| SCHEMBL16440384 | 0.78 | MAPT (0.73) | RXFP1MAPTSMN1; SMN2LMNATP53 | |
| SCHEMBL18166729 | 0.78 | RXFP1 (0.64) | RXFP1MAPTTP53TSHRKDM4E | |
| SCHEMBL12260494 | 0.78 | SMN1; SMN2 (0.76) | RXFP1MAPTSMN1; SMN2LMNATP53 | |
| SCHEMBL18166709 | 0.78 | SMN1; SMN2 (0.73) | RXFP1MAPTSMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-101801362-B | Methods and compositions for treating disorders | HYDRA BIOSCIENCES INC | 2014-01-22 | — | — | CN | disclosed |
| CN-101801362-A | methods and compositions for treating disorders | HYDRA BIOSCIENCES INC | 2010-08-11 | — | — | CN | disclosed |